{"schema_version":"1.0","hypothesis_id":38768,"triple":{"drug":"Adalimumab","drug_canonical":"adalimumab","mediator":"anti-drug antibodies","mediator_canonical":"anti-drug antibodies","outcome":"loss of response","outcome_canonical":"loss of response"},"domain":{"domain":"cross_domain","source":"rheumatoid_arthritis","target":"inflammatory_bowel_disease"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1111/jdv.19089","pmid":"37014287","year":2023,"roles":["drug_mediator"],"title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial","journal":"J Eur Acad Dermatol Venereol","work_id":296903,"publication_date":"2023-04-04"},{"doi":"10.1080/00365521.2023.2278424","pmid":"37961895","year":2023,"roles":["mediator_outcome"],"title":"Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies","journal":"Scand J Gastroenterol","work_id":281746,"publication_date":"2023-11-14"},{"doi":"10.1111/apt.16605","pmid":"34559428","year":2021,"roles":["mediator_outcome"],"title":"Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease","journal":"Aliment Pharmacol Ther","work_id":272352,"publication_date":"2021-09-24"},{"doi":"10.1177/1756283x17750355","pmid":"29383030","year":2018,"roles":["mediator_outcome"],"title":"Immunogenicity of biologics in inflammatory bowel disease","journal":"Ther Adv Gastroenterol","work_id":268111,"publication_date":"2018-01-01"}],"source_paper_count":4,"extracted_claims":[{"side":"drug_mediator","object":"anti-drug antibodies","context":"in psoriasis patients","subject":"adalimumab","work_id":296903,"claim_id":245362,"polarity":"positive","predicate":"induces","confidence":0.9,"extraction_run_id":29},{"side":"mediator_outcome","object":"loss of response","context":"in inflammatory bowel disease patients","subject":"anti-drug antibodies","work_id":268111,"claim_id":211328,"polarity":"positive","predicate":"associated_with","confidence":0.85,"extraction_run_id":31},{"side":"mediator_outcome","object":"loss of response","context":"in patients on anti-TNFα therapy","subject":"anti-drug antibodies","work_id":272352,"claim_id":230859,"polarity":"positive","predicate":"associated_with","confidence":0.7,"extraction_run_id":31},{"side":"mediator_outcome","object":"loss of response","context":"in patients with inflammatory bowel disease","subject":"anti-drug antibodies","work_id":281746,"claim_id":265178,"polarity":"positive","predicate":"causes","confidence":0.9,"extraction_run_id":31}],"extracted_claim_count":4,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[29,31]},"bridge":{"a_to_b_predicate":"induces","b_to_c_predicate":"associated_with","a_to_b_evidence_count":1,"b_to_c_evidence_count":3,"edge_support_log_ab":0.6931471805599453,"edge_support_log_bc":1.3862943611198906,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.20794415416798356,"score":0.20794415416798356,"quality_tier":"mid","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:40.945575+00:00"}